ERBB2 and neoplasm: The fact that median OS in both arms of the PALOMA-2 trial was over 50 months [42], whereas real-world data in Dutch women with ER+/HER2- metastatic breast cancer treated with systemic therapy found a median OS of 33 months [43], suggests that the PALOMA-2 population had better patient- and tumor characteristics than those seen in daily practice.